JAK3 and cancer: In addition, mutations of cytokine- and growth factor receptors such as IL7Ra can result in IL-7 receptor hypersensitivity leading to elevated JAK3 activation [53] indicating multilevel control of JAK activation (and deregulation) in cancer.